XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities:    
Net loss $ (32,768) $ (63,888)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 7,947 10,915
Depreciation and amortization 718 721
Amortization of debt issuance costs 51 50
(Accretion of discount) amortization of premium on short-term investments (474) 104
Impairment of property and equipment 154 47
Loss on disposal of property and equipment   96
Change in operating assets and liabilities:    
Accounts receivable 601 (5,604)
Inventory 2,514 (8,088)
Prepaid expenses and other assets 906 (405)
Accounts payable 840 4,423
Accrued clinical and manufacturing liabilities (3,195) 13,561
Accrued payroll and employee liabilities (3,906) (3,049)
Other accrued and other non-current liabilities 1,712 7,178
Net cash used in operating activities (24,900) (43,939)
Investing activities:    
Purchases of short-term investments (13,942) (38,023)
Maturities and sales of short-term investments 51,000 49,957
Purchases of property and equipment (224) (1,044)
Proceeds from the sale of property and equipment   56
Net cash provided by investing activities 36,834 10,946
Financing activities:    
Payments for stock issued under the equity incentive plan (208) (637)
Net cash used in financing activities (208) (637)
Net increase (decrease) in cash and cash equivalents 11,726 (33,630)
Cash and cash equivalents at beginning of year 15,364 90,541
Cash and cash equivalents at end of period $ 27,090 $ 56,911